Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — Q1 2023 Earnings Presentation
18 slides from Niagen Bioscience's earnings presentation, May 10, 2023
Slide 1: ChromaDex Earnings Conference Call First Quarter 2023
ChromaDex Earnings Conference Call First Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | May 10, 2023
Slide 2: Safe Harbor Statement
This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-
Slide 3: Q1 2023 & Recent Highlights
Q1 2023 & Recent Highlights • Total company and Tru Niagen® net sales up 31% and 18% YoY, respectively, with 12% growth in E-Commerce. • Delivered strong gross margins of 59.9% and a $2.8 million reduction in operating expenses, reflecting financial discipline. • Selling and marketing expense was lo
Slide 4: Management Team
Management Team Rob Fried Brianna Gerber Chief Executive Officer Chief Financial Officer E-commerce & Over 20 years of diverse entertainment industry experience in investment executive management and finance at the Capital Group, Savoy Pictures, Columbia Mattel, and ChromaDex Pictures, Fried Films,
Slide 5: Financial Highlights
Financial Highlights 5 The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019)
Slide 6: Q1 2023 Net Sales Mix
Q1 2023 Net Sales Mix Q1 2023 Q1 2022 Watson's & Other B2B E-Commerce Watson's & Other B2B E-Commerce 24% 63% 24% 54% $22.6 MM $17.3 MM Niagen® Ingredient 17% Niagen® Ingredient 7% Analytical Reference Analytical Reference Other Ingredients Standards & Services Other Ingredients Standards & Services
Slide 7: Q1 2023 Net Sales
Q1 2023 Net Sales Q1 2023 Net Sales Growth Rates ($ in millions) YoY % (vs Q1 2022) E-Commerce 12.2 +12% $17.6 Watson's & Other B2B 5.4 +36% Niagen® Ingredient 3.9 +245% Analytical Reference (11)% 0.8 Standards & Services (24)% Other Ingredients 0.2 Total +31% Tru Niagen® business up 18% year-over-y
Slide 8: 2021 – 2023 YTD Net Sales Summary
2021 – 2023 YTD Net Sales Summary ($ in millions) 2021 2022 2023 Description Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 E-Commerce 9.6 10.6 10.5 11.1 41.8 10.9 12.0 11.3 11.1 45.3 12.2 Watsons 1.6 2.9 2.6 2.2 9.3 2.6 1.5 2.6 3.3 10.0 3.7 Other B2B 1.3 1.8 1.6 0.8 5.6 1.4 1.0 0.7 1.7 4.8 1.7 Total TRU NIAGEN 1
Slide 9: Q1 2023 vs Q1 2022 Key P&L Metrics
Q1 2023 vs Q1 2022 Key P&L Metrics (in thousands) Q1 2023 Q1 2022 Notes Tru Niagen® business up 18% driven by growth in E-Commerce (up Net Sales $22,556 $17,259 +12%) and higher B2B sales. Niagen® ingredient sales up 245% driven by increased demand from new and existing partners. Gross Profit 13,518
Slide 10: Adjusted EBITDA Summary
Adjusted EBITDA Summary ChromaDex Corporation and Subsidiaries Reconciliation of Non-GAAP Finanical Measures (In thousands) Three months ended Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Net loss, as reported $ (7,381) $ (5,566) $ (8,856) $ (5,325) $ (7,740) $ (6,397) $ (
Slide 11: Q1 2023 Operating Loss vs Q1 2022
Q1 2023 Operating Loss vs Q1 2022 +$6.3 MM -$0.6 MM (in millions) — (1.0) 0.3 0.6 (2.0) 0.7 (0.3) (0.2) (0.1) (2.0) 1.5 (3.0) (4.0) 3.2 (5.0) (6.0) (7.0) (8.0) (7.7) (9.0) Q1 2022 Volume Legal Equity Comp Severance Sales & Other G+A Gross Margin Research and Q1 2023 Operating (G+A) and Marketing Dec
Slide 12: Quarterly Balance Sheet Highlights
Quarterly Balance Sheet Highlights (in thousands) 12/31/20 12/31/21 3/31/22 6/30/22 9/30/22 12/31/22 3/31/23 Key Drivers (YoY for 2023 YTD) Cash $16,697 $28,219 $20,993 $17,072 $13,262 $20,441 $23,141 Driven by cash provided by operations Driven by higher total net sales and improvements Inventory 1
Slide 13: Quarterly Cash Flow Highlights
Quarterly Cash Flow Highlights (in thousands) FY 2020 FY 2021 3/31/22 6/30/22 9/30/22 12/31/2022 FY 2022 3/31/23 Net Loss $ (19,925) $(27,128) $(7,740) $(6,397) $(985) (4) $(1,418) $(16,540) (4) $(1,902) Working Capital 383 (1) (4,915) (1,923) 923 (4,461) (4) (466) (5,927) (4) 2,644 Cash From / (Use
Slide 14: 2023 Financial Outlook
2023 Financial Outlook (in thousands) 2021 Actual 2022 Actual 2023 Full Year Outlook Key Drivers • Conservative end includes steady growth from E-commerce business & recurring revenues At least 12.5% growth, with realistic possibility from established partnerships as well as some of significantly gr
Slide 15: The Science
The Science 15 The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019)
Slide 16: Scientific Advisory Board
Scientific Advisory Board NOBEL PRIZE WINNERS | CHEMISTRY Charles Brenner, Ph.D. Roger Kornberg, Ph.D. Rudolph Tanzi, Ph.D. Alfred E Mann Family Chairman Kennedy Professor of Foundation Chair, Professor of Structural Neurology Department of Diabetes & Biology Harvard University Cancer Metabolism Sta
Slide 17: Basic Physiological Functions are NAD+ Dependent
Basic Physiological Functions are NAD+ Dependent INTRINSIC CAPACITY DOMAIN Based on World Health Organization’s definition VITALITY LOCOMOTION COGNITION SENSORY PSYCHOLOGICAL Energy metabolism Muscle strength Memory Mood Vision Hormonal function Balance Intelligence Hearing Emotional vitality Cardio
Slide 18: Contact Info
Contact Info: T: +1(949) 356-1620 InvestorRelations@ChromaDex.com www.chromadex.com Where to buy TRU NIAGEN® TruNiagen.com Amazon.com The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redis